Search results
Results From The WOW.Com Content Network
Trading at a forward P/E of 25 and a price/earnings-to-growth multiple of around 0.70, ... and AstraZeneca Plc wasn’t one of them. The 10 stocks that made the cut could produce monster returns ...
AstraZeneca expects a sales hit in China, one of its most important international markets. U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its ...
For premium support please call: 800-290-4726 more ways to reach us
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide. [14]
AstraZeneca claimed the deal undervalued the company. [15] 4 2014 Pfizer: Astra Zeneca: 99 127 AstraZeneca claimed the deal undervalued the company. [16] 5 1999 Pfizer: Warner–Lambert: 82.4 151 Pfizer made a hostile bid, just after the announcement of a $72 billion deal with Wyeth, the eventual purchase price would be in excess of $90 billion ...
The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. AstraZeneca bets on new cancer treatments with $2 billion Fusion ...
Total revenue rose 17% on a constant-currency basis to $12.94 billion for the three months ended June, while core earnings came in at $1.98 per share, compared with analysts' average expectation ...
Together with the domestic Sanofi (NASDAQ: SNY), Pfizer, AstraZeneca will together invest €1.87 billion which is more than $2 billion to expand their operations in the country.